Please login to the form below

kidney disease

This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.

Ardelyx gets second kidney disease trial win for tenapanor

Drug hit primary and all secondary endpoints. California biotech Ardelyx has a second positive trial for its lead drug tenapanor in chronic kidney disease (CKD), as it waits for an FDA

Latest news

GSK files anaemia drug daprodustat in Japan, its first market

Around 3.5 million people in Japan could access the drug. GlaxoSmithKline (GSK) has kicked off its marketing applications for daprodustat, a new oral drug for anaemia associated with chronic kidney ... disease (CKD), in Japan.
Boehringer posts solid first half as business revamp beds in

Jardiance, partnered with Eli Lilly, has been benefitting from a new claim on the label arising from the EMPA-REG OUTCOME trial, which showed the drug could cut cardiovascular and kidney ... Meanwhile, Boehringer is also testing the impact of
Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

for their diabetic kidney disease therapy imeglimin. ... The study tested the ‘glimin’ drug in subjects with type 2 diabetes and moderate to severe (stage 3b/4) chronic kidney disease (CKD), and backed up the safety, tolerability and clinical
Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12%

non-fatal stroke – as well as a 15% drop in the development of kidney disease compared to placebo over more than five years of follow-up. ... period. More than 46% of participants were women, and less than a third had previous cardiovascular disease.
AZ says Farxiga cuts kidney disease in type 2 diabetes

to moderate chronic kidney disease, or both, according to the trial investigators in their study paper. ... These results emphasise the value of SGLT2 inhibitors as an important component of both prevention and treatment of chronic kidney disease

More from news
Approximately 19 fully matching, plus 131 partially matching documents found.

Latest Intelligence

25 Women Leaders in UK Healthcare

The firm has just signed a long-term collaboration with AZ for the discovery of new drugs for chronic kidney disease and idiopathic pulmonary fibrosis (IPF). ... disease and applying machine learning, artificial intelligence and collapsing analysis to
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

of JAK proteins is an established method of controlling the symptoms of this disease. ... The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
China: AstraZeneca’s new engine for growth and innovation

FibroGen in China for patients with anaemia in chronic kidney disease. ... AstraZeneca’s goal is to realise complete disease management, covering prevention, screening, diagnosis, treatment and follow- up.
The invisible army

Studies with COPD and chronic kidney disease patients indicate that carers can have a positive influence on patient adherence to medication and healthy behaviours, thus driving positive outcomes in the process.
Deal Watch December 2016

1, 000. Akebia (US). Otsuka (Japan). Licence (US). Vadadustat: oral hypoxia-inducible factor (HIF) stabiliser in phase III for anaemia of chronic kidney disease. ... inflammatory bowel disease and multiple sclerosis.

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

Sanifit appoints Alexander Gold chief medical officer

Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.
Spectrum appoints chief medical officer

of iron deficiency anaemia in adult patients with chronic kidney disease.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Its Know Your Numbers week

One in 4 adults in the UK has high blood pressure so the risk of developing heart disease, heart attacks, strokes, kidney disease and vascular dementia are very real. ... Lack of exercise. Being overweight. Chronic Kidney Disease. Regularly drinking
What are you doing, Dave?

parents. Google's DeepMind is exploring the use of AI in managing head and neck cancer, acute kidney injury, and detection of eye disease. ... The IBM Watson supercomputer is also being used to help manage cancer, as well as analysing data on genes,
Lighthouse Medical Communications US makes the list of finalists for the 2018 PM360 Trailblalzer Awards

This exciting news is a true testament to the American Kidney Fund’s commitment to improving the lives of patients with chronic kidney disease. ACT on Anemia was one of a ... ACT on Anemia - Anemia in Chronic Kidney Disease, is a multi-channel
Making good practice common practice in rare disease

However, fatigue scores can’t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Events Executive: DOE

Account Manager – Healthcare advertising: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Client Services Director- Flexible Working: Negotiable

Senior Medical Writer: Competitive salary plus benefits

Subscribe to our email news alerts

PMHub

Add my company

mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...